FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385705907> ?p ?o ?g. }

• W4385705907 endingPage "e3758967" @default.
• W4385705907 startingPage "e3758967" @default.
• W4385705907 abstract "Topic: 22. Stem cell transplantation - Clinical Background: Chemotherapy-induced nausea and vomiting (CINV) are adverse events that compromise quality of life and treatment compliance in patients undergoing autologous hematopoietic stem cell transplantation (ASCT). Polychemotherapy regimens, used as conditioning regimens for ASCT in lymphomas, and high-dose melphalan (≥140 mg/mq), used in multiple myeloma (MM) have high emetogenic risk. The three drugs currently used for antiemetic prophylaxis are serotonin (5-HT3) receptor antagonists as Ondansetron, NK1 receptor antagonists and dexamethasone. Netupitant-Palonosetron (NEPA), an oral formulation derived from the combination of Netupitant (NK1-RA) and Palonsetron, has been approved as prophylaxis of CINV but its experience is still limited. Aims: The primary aim was to compare the efficacy of Ondansetron and NEPA in terms of reduction of CINV in patients affected by lymphoma or MM undergone ASCT. The secondary aims included comparing the duration of CINV, based on the use of Ondansetron or NEPA, and their safety profile in terms of reduction of extrahaematological toxicity. Methods: In this retrospective monocentric study, we enrolled 76 patients (48 with MM and 28 with lymphoma), who underwent ASCT between March 2021 and March 2022, with a median age of 61 years. All patients with MM received high dose of melphalan, those with lymphoma received FEAM. Regarding antiemetics, patients who received NEPA were 33 with MM (one shot the day of conditioning) and 21 with lymphoma (every 72 hours during conditioning). Instead, 14 patients with MM and 8 with lymphoma received Ondansetron twice daily during conditioning. The Likert scale was used to measure the effectiveness of antiemetics. Results: Fifty patients (65%) reported CINV of any grade. In particular, the group experiencing CINV included about half of patients treated with NEPA (56%) and almost all those treated with Ondansetron (91%). Among the 26 patients who didn’t report CINV (35%), the majority received NEPA (92%) (P = 0.0032) (Figure 1a). Focusing on patients with MM, 59% of those treated with NEPA and 93% of those treated with Ondansetron reported CINV. Fifteen patients did not experience CINV (32%) and almost all (93%) had been treated with NEPA (P = 0.037) (Figure 1b). Sixty-one percent of the 28 patients with lymphoma reported CINV (P= 0.1914) (Figure 1c). Mean duration of CINV was significantly shorter for patients treated with NEPA than for those treated with Ondansetron (4.8 days vs 9.2 days) (P= 0.002) (Figure 1d). Regarding extraematological toxicity of chemotherapy, as mucositis and diarrhea, we didn’t find any significant difference between the two groups of patients. Regarding the outcome, 37% of patients had complete response to NEPA, 28% had controlled nausea and 31% had uncontrolled nausea, while only 5% of patients had complete response and 95% had uncontrolled nausea in the Ondansetron group (Figure 1e). According to CTCAE, 69% of patients receiving NEPA had grade 1 nausea and 6% had none, while 85% of patients receiving Ondansetron had grade 2 nausea and none had none. Summary/Conclusion: In our experience, NEPA has shown superiority in the prevention of CINV, in highly emetogenic regimens in both patients with myeloma or lymphoma, with advantages on the severity and the duration of CINV. Given the high burden of CINV in the whole population analyzed in the study, regardless of the antiemetic used, it would be useful to identify patients at greatest risk and standardize CINV prophylaxis and treatment protocols depending on the different chemotherapy regimens and their emetogenic risk.Keywords: Myeloma, Lymphoma, CINV prophylaxis, Autologous hematopoietic stem cell transplantation" @default.
• W4385705907 created "2023-08-10" @default.
• W4385705907 creator A5004621120 @default.
• W4385705907 creator A5005592897 @default.
• W4385705907 creator A5024590456 @default.
• W4385705907 creator A5026661663 @default.
• W4385705907 creator A5028160176 @default.
• W4385705907 creator A5030806032 @default.
• W4385705907 creator A5032650523 @default.
• W4385705907 creator A5032734899 @default.
• W4385705907 creator A5032920108 @default.
• W4385705907 creator A5038416326 @default.
• W4385705907 creator A5042424261 @default.
• W4385705907 creator A5044228908 @default.
• W4385705907 creator A5045565716 @default.
• W4385705907 creator A5049172299 @default.
• W4385705907 creator A5054304877 @default.
• W4385705907 creator A5058572001 @default.
• W4385705907 creator A5058720616 @default.
• W4385705907 creator A5070219522 @default.
• W4385705907 creator A5086479763 @default.
• W4385705907 creator A5092620342 @default.
• W4385705907 date "2023-08-01" @default.
• W4385705907 modified "2023-10-01" @default.
• W4385705907 title "P1305: NEPA VERSUS ONDANSETRON FOR THE PREVENTION OF CINV IN PATIENTS WITH MULTIPLE MYELOMA OR LYMPHOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. A MONOCENTRIC REAL-LIFE EXPERIENCE." @default.
• W4385705907 doi "https://doi.org/10.1097/01.hs9.0000972108.37589.67" @default.
• W4385705907 hasPublicationYear "2023" @default.
• W4385705907 type Work @default.
• W4385705907 citedByCount "0" @default.
• W4385705907 crossrefType "journal-article" @default.
• W4385705907 hasAuthorship W4385705907A5004621120 @default.
• W4385705907 hasAuthorship W4385705907A5005592897 @default.
• W4385705907 hasAuthorship W4385705907A5024590456 @default.
• W4385705907 hasAuthorship W4385705907A5026661663 @default.
• W4385705907 hasAuthorship W4385705907A5028160176 @default.
• W4385705907 hasAuthorship W4385705907A5030806032 @default.
• W4385705907 hasAuthorship W4385705907A5032650523 @default.
• W4385705907 hasAuthorship W4385705907A5032734899 @default.
• W4385705907 hasAuthorship W4385705907A5032920108 @default.
• W4385705907 hasAuthorship W4385705907A5038416326 @default.
• W4385705907 hasAuthorship W4385705907A5042424261 @default.
• W4385705907 hasAuthorship W4385705907A5044228908 @default.
• W4385705907 hasAuthorship W4385705907A5045565716 @default.
• W4385705907 hasAuthorship W4385705907A5049172299 @default.
• W4385705907 hasAuthorship W4385705907A5054304877 @default.
• W4385705907 hasAuthorship W4385705907A5058572001 @default.
• W4385705907 hasAuthorship W4385705907A5058720616 @default.
• W4385705907 hasAuthorship W4385705907A5070219522 @default.
• W4385705907 hasAuthorship W4385705907A5086479763 @default.
• W4385705907 hasAuthorship W4385705907A5092620342 @default.
• W4385705907 hasBestOaLocation W43857059071 @default.
• W4385705907 hasConcept C126322002 @default.
• W4385705907 hasConcept C143998085 @default.
• W4385705907 hasConcept C2776712918 @default.
• W4385705907 hasConcept C2777170512 @default.
• W4385705907 hasConcept C2777408962 @default.
• W4385705907 hasConcept C2778684742 @default.
• W4385705907 hasConcept C2779050716 @default.
• W4385705907 hasConcept C2779924295 @default.
• W4385705907 hasConcept C2780580376 @default.
• W4385705907 hasConcept C2780884295 @default.
• W4385705907 hasConcept C2911091166 @default.
• W4385705907 hasConcept C42219234 @default.
• W4385705907 hasConcept C71924100 @default.
• W4385705907 hasConceptScore W4385705907C126322002 @default.
• W4385705907 hasConceptScore W4385705907C143998085 @default.
• W4385705907 hasConceptScore W4385705907C2776712918 @default.
• W4385705907 hasConceptScore W4385705907C2777170512 @default.
• W4385705907 hasConceptScore W4385705907C2777408962 @default.
• W4385705907 hasConceptScore W4385705907C2778684742 @default.
• W4385705907 hasConceptScore W4385705907C2779050716 @default.
• W4385705907 hasConceptScore W4385705907C2779924295 @default.
• W4385705907 hasConceptScore W4385705907C2780580376 @default.
• W4385705907 hasConceptScore W4385705907C2780884295 @default.
• W4385705907 hasConceptScore W4385705907C2911091166 @default.
• W4385705907 hasConceptScore W4385705907C42219234 @default.
• W4385705907 hasConceptScore W4385705907C71924100 @default.
• W4385705907 hasIssue "S3" @default.
• W4385705907 hasLocation W43857059071 @default.
• W4385705907 hasLocation W43857059072 @default.
• W4385705907 hasOpenAccess W4385705907 @default.
• W4385705907 hasPrimaryLocation W43857059071 @default.
• W4385705907 hasRelatedWork W1124263639 @default.
• W4385705907 hasRelatedWork W1967924577 @default.
• W4385705907 hasRelatedWork W2185330854 @default.
• W4385705907 hasRelatedWork W2233598186 @default.
• W4385705907 hasRelatedWork W2395318026 @default.
• W4385705907 hasRelatedWork W2621644069 @default.
• W4385705907 hasRelatedWork W3096722963 @default.
• W4385705907 hasRelatedWork W3191363630 @default.
• W4385705907 hasRelatedWork W4245250147 @default.
• W4385705907 hasRelatedWork W65357274 @default.
• W4385705907 hasVolume "7" @default.
• W4385705907 isParatext "false" @default.
• W4385705907 isRetracted "false" @default.
• W4385705907 workType "article" @default.